<DOC>
	<DOC>NCT01181089</DOC>
	<brief_summary>This is a prospective, randomized, multicenter, dose escalation study to determine subject safety, pharmacokinetic, and pharmacodynamic responses in patients with SPMS</brief_summary>
	<brief_title>Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)</brief_title>
	<detailed_description>This study is a prospective, randomized, placebo-controlled, blinded, dose escalation study of 3 to 4 cohorts with defined number of patients per cohort receiving active drug or placebo for a period of 4 months followed by safety monitoring for an additional 4 months after the last dose</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
	<criteria>A diagnosis of Secondary Progressive Multiple Sclerosis Aged 18 to 57 years old, at the time of informed consent History of clinically important (as determined by the investigator) cardiac, endocrinologic, pulmonary, neurologic, immune, psychiatric, hepatic, renal or hematologic insufficiency or any other major disease other than MS ( Multiple Sclerosis) Inability in the opinion of the Investigator to comply with study requirements Other protocoldefined criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>57 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>